Systemic Lupus Erythematosus

FDA reviews Gazyva for systemic lupus after ALLEGORY shows stronger responses, fewer flares and steroid use—potential first anti‑CD20 option for SLE.

Ronald F. van Vollenhoven, MD, PhD, discusses 5-year real-world follow-up that show belimumab stays broadly safe in SLE.

The decision is supported by data from the phase 2b JASMINE study which will be presented at a future medical meeting.

Subcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.

Cuda discussed the link between SLE disease activity and cognitive deficits,

New research at ACR 2025 highlights the link between cognitive impairment and disease activity in SLE.

Phase 2 trial shows ianalumab achieves sustained lupus disease control, supports steroid tapering, and increases time in remission over 1 year.

Phase 3 data show dapirolizumab pegol improved remission and disease stability in lupus; a second trial and patient-reported outcomes are now underway.

At ACR 2025, Vital discussed phase 3 data showing dapirolizumab pegol improved remission and stabilized disease activity in patients with lupus.

Jin discussed new evidence supporting the immune-modulating effects of low-dose IL-2 at ACR 2025.

However, a notable higher rate of treatment-related adverse events warrants caution.